Navigation Links
QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
Date:9/15/2009

TOKYO, September 16 /PRNewswire-FirstCall/ --

- Promising Efficacy and Tolerability for Novel Combination COPD Therapy

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announce that Novartis have presented the results of their two Phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual congress of the European Respiratory Society (ERS) in Vienna. QVA149 is a novel once-daily, dry powder fixed dose bronchodilator combination of the once-daily beta2-agonist QAB149 (indacaterol) and the LAMA, NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD).

NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to US$375 million in milestones as well as royalties on product sales.

One of the randomised, cross-over double-blind, placebo-controlled studies compared inhaled administration of QVA149 300/50 (QAB149 300 micrograms + NVA237 50 micrograms) with two doses of QAB149 (300 micrograms, 600 micrograms) to evaluate bronchodilatory effect in terms of trough FEV1 (forced expiratory volume in one second) after 7 days of therapy. One hundred and thirty-five patients with moderate to severe COPD completed the study with an observed clinically relevant mean improvement in trough FEV1 between QVA149 and placebo on Day 7 of 226 mL. Similarly, the estimated mean treatment differences between QVA149 and QAB149 300 micrograms and 600micrograms were 123 mL and 117 mL, respectively. Similar results were observed on Day 1 of the study and both QVA149 and QAB149 were well tolerated.

The other placebo-controlled trial evaluated the safety and tolerability of 3 doses of QVA149 (600/100, 300/100 and 150/100) and QAB149 (300 micrograms) in 255 patients during 14 days of treatment. In this study, QVA149 had no significant effect on change in 24 hour me
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... AVIV, Israel, May 6 InspireMD, developers of,MGuard(TM), announced ... the,iMOS registry. MGuard(TM) was successfully implanted at the General,University ... Jan Horak. , InspireMD plans ... is a post market study, will be conducted in ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the first quarter ended March 31, 2009, and provided ... pivotal Phase 3 SPEAR trial of picoplatin for the ...
Cached Medicine Technology:InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9
(Date:7/11/2014)... AngelWeddingDress is now providing worldwide clients ... collections ”. When it comes to buying summer wedding ... with the unlimited stock of beautiful wedding gowns. Recently, ... wonderful summer wedding gowns. , The company’s current ... keep pace with the newest fashion trends. The top ...
(Date:7/11/2014)... July 11, 2014 Shoulder instability is ... of return to play has not been regularly determined ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... is approximately 90 percent no matter what the stabilization ... success rate of return to play following shoulder stabilization ...
(Date:7/11/2014)... SEATTLE, WA Re-tearing a repaired knee Anterior Cruciate ... study being presented today at the American Orthopaedic Society ... and patient education regarding modifiable risk factors may minimize ... "Our research suggests that a few risk factors such ... may point to the possibility of re-injury," said lead ...
(Date:7/11/2014)... Austin, TX (PRWEB) July 11, 2014 ... with their customers and to show more about their ... http://www.kennrenner.com/buyaveryranch/ and view their home videos online, ... , Avery Ranch is Austin, Texas’ premiere golf course ... the city limits of Austin. Avery Ranch features an ...
(Date:7/11/2014)... Wearing the school motto on their shirts, ... staff came together this past Saturday morning ready to wave, ... the Homer Township Independence Day Parade. The theme of ... , Everest community recognized the theme of A Salute ... and blue. The blue Everest balloons filled with helium ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:Avery Ranch Announces Their New Website to Better Connect with Customers 2Health News:Everest Academy Participates in the Homer Township Independence Day Parade 2
... (OTC,Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of ... has,changed to CHRX from PMQC. The Company,s common stock ... About Chem Rx Corporation, Founded more than ... of institutional pharmacy services in the New York City,metropolitan ...
... monitor/defibrillators help ensure safety at 112th ... Royal Philips,Electronics (NYSE: PHG , AEX: PHI) ... automated external defibrillators (AEDs) and advanced life,support (ALS) ... run on April 21. The strategic deployment of ...
... 18 Ferring Pharmaceuticals Inc.,has announced that its ... serve as the sponsor for masters track club,Sprint ... commitment to active aging," said,Alex Drigan, Product Director, ... of track and believe that they can inspire ...
... April 18 Chronic pain in the ball ... Metatarsalgia ( http://www.OurHealthNetwork.com/metatarsalgia ) is a,catch-all term ... dropped metatarsal heads, bursitis, arthritis, sesamoiditis, and,Morton,s neuroma. ... each step for them a nightmare., When ...
... density affects memory and psychomotor speed, study says , , ... solvents in products such as paints and dry cleaning ... report. , These abnormalities play a role in ... team conclude in the April issue of the ...
... PROTECTION IN A SUNSCREEN WITH ... MEXORYL(TM) SX, ... worldwide, announces the FDA approval,of ANTHELIOS 40 with the highest photostable UVA ... is a,revolutionary outdoor use sunscreen for the face and body, specifically,tested for ...
Cached Medicine News:Health News:Chem Rx Corporation Changes Ticker Symbol to CHRX 2Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 2Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 3Health News:Philips Supports the Boston Marathon as the Sole Provider of Life-Saving Medical Devices 4Health News:Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club 2Health News:Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club 3Health News:Metatarsalgia (or Forefoot Pain) Affects Millions of Americans; Podiatrists Discuss How to Relieve Metatarsalgia Pain 2Health News:Chronic Exposure to Solvents Disturbs Brain's Wiring 2Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 2Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 3Health News:ANTHELIOS 40 Sunscreen with Mexoryl(TM) SX From the brand trusted for over 15 years worldwide to offer high UVA protection 4
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: